WO2014190361A3 - Feeder-free derivation of human-induced pluripotent stem cells with synthetic messenger rna - Google Patents

Feeder-free derivation of human-induced pluripotent stem cells with synthetic messenger rna Download PDF

Info

Publication number
WO2014190361A3
WO2014190361A3 PCT/US2014/040362 US2014040362W WO2014190361A3 WO 2014190361 A3 WO2014190361 A3 WO 2014190361A3 US 2014040362 W US2014040362 W US 2014040362W WO 2014190361 A3 WO2014190361 A3 WO 2014190361A3
Authority
WO
WIPO (PCT)
Prior art keywords
stem cells
pluripotent stem
induced pluripotent
feeder
human
Prior art date
Application number
PCT/US2014/040362
Other languages
French (fr)
Other versions
WO2014190361A2 (en
Inventor
Jiwu Wang
Original Assignee
Allele Biotechnology And Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allele Biotechnology And Pharmaceuticals, Inc. filed Critical Allele Biotechnology And Pharmaceuticals, Inc.
Priority to JP2016514171A priority Critical patent/JP6971574B2/en
Priority to MX2015015840A priority patent/MX2015015840A/en
Priority to EP21154853.2A priority patent/EP3904504A1/en
Priority to EP14801588.6A priority patent/EP2997130A4/en
Priority to CN201480033794.XA priority patent/CN105555949A/en
Priority to SG11201509368PA priority patent/SG11201509368PA/en
Publication of WO2014190361A2 publication Critical patent/WO2014190361A2/en
Publication of WO2014190361A3 publication Critical patent/WO2014190361A3/en
Priority to HK16110689.7A priority patent/HK1222675A1/en
Priority to HK16112614.3A priority patent/HK1224335A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0696—Artificially induced pluripotent stem cells, e.g. iPS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C12N2501/602—Sox-2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C12N2501/603—Oct-3/4
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C12N2501/605—Nanog
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C12N2501/608—Lin28
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/998—Proteins not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/13—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells
    • C12N2506/1307—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells from adult fibroblasts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Transplantation (AREA)
  • Immunology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Dermatology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present disclosure relates generally to novel methods and compositions for using engineered reprogramming factor(s) for the creation of induced pluripotent stem cells (iPSCs) through a kinetically controlled process. Specifically, this disclosure relates to establishing combinations of reprogramming factors, including fusions between conventional reprogramming factors with transactivation domains, optimized for reprogramming various types of cells. More specifically, the exemplary methods disclosed herein can be used for creating induced pluripotent stem cells from various mammalian cell types, including human fibroblasts. Exemplary methods of feeder-free derivation of human induced pluripotent stem cells using synthetic messenger RNA are also disclosed.
PCT/US2014/040362 2013-05-13 2014-05-30 Feeder-free derivation of human-induced pluripotent stem cells with synthetic messenger rna WO2014190361A2 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
JP2016514171A JP6971574B2 (en) 2013-05-13 2014-05-30 Feeder-free induction of human induced pluripotent stem cells by synthetic messenger RNA
MX2015015840A MX2015015840A (en) 2013-05-13 2014-05-30 Feeder-free derivation of human-induced pluripotent stem cells with synthetic messenger rna.
EP21154853.2A EP3904504A1 (en) 2013-05-13 2014-05-30 Feeder-free derivation of human-induced pluripotent stem cells with synthetic messenger rna
EP14801588.6A EP2997130A4 (en) 2013-05-13 2014-05-30 Feeder-free derivation of human-induced pluripotent stem cells with synthetic messenger rna
CN201480033794.XA CN105555949A (en) 2013-05-13 2014-05-30 Feeder-free derivation of human-induced pluripotent stem cells with synthetic messenger RNA
SG11201509368PA SG11201509368PA (en) 2013-05-13 2014-05-30 Feeder-free derivation of human-induced pluripotent stem cells with synthetic messenger rna
HK16110689.7A HK1222675A1 (en) 2013-05-13 2016-09-08 Feeder-free derivation of human-induced pluripotent stem cells with synthetic messenger rna rna
HK16112614.3A HK1224335A1 (en) 2013-05-13 2016-11-02 Feeder-free derivation of human-induced pluripotent stem cells with synthetic messenger rna rna

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13/893,166 US10155929B2 (en) 2012-05-13 2013-05-13 Feeder-free derivation of human-induced pluripotent stem cells with synthetic messenger RNA
US13/893,166 2013-05-13

Publications (2)

Publication Number Publication Date
WO2014190361A2 WO2014190361A2 (en) 2014-11-27
WO2014190361A3 true WO2014190361A3 (en) 2015-07-30

Family

ID=51939013

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2014/040362 WO2014190361A2 (en) 2013-05-13 2014-05-30 Feeder-free derivation of human-induced pluripotent stem cells with synthetic messenger rna

Country Status (8)

Country Link
US (1) US10155929B2 (en)
EP (2) EP2997130A4 (en)
JP (2) JP6971574B2 (en)
CN (1) CN105555949A (en)
HK (2) HK1222675A1 (en)
MX (2) MX2015015840A (en)
SG (2) SG11201509368PA (en)
WO (1) WO2014190361A2 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9376669B2 (en) 2012-11-01 2016-06-28 Factor Bioscience Inc. Methods and products for expressing proteins in cells
US9422577B2 (en) 2011-12-05 2016-08-23 Factor Bioscience Inc. Methods and products for transfecting cells
US12006508B2 (en) 2020-06-25 2024-06-11 Factor Bioscience Inc. Methods and products for expressing proteins in cells

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10155929B2 (en) * 2012-05-13 2018-12-18 Allele Biotechnology & Pharmaceuticals, Inc. Feeder-free derivation of human-induced pluripotent stem cells with synthetic messenger RNA
ES2729563T3 (en) * 2012-05-13 2019-11-04 Allele Biotechnology & Pharmaceuticals Inc Feeder-free derivation of human induced pluripotent stem cells with synthetic messenger RNA
US10119150B2 (en) 2012-05-13 2018-11-06 Allele Biotechnology & Pharmaceuticals, Inc. Feeder-free Derivation of human-induced pluripotent stem cells with synthetic messenger RNA
CA2876868A1 (en) * 2012-06-13 2013-12-19 Stemgent, Inc. Methods of preparing pluripotent stem cells
US9770489B2 (en) 2014-01-31 2017-09-26 Factor Bioscience Inc. Methods and products for nucleic acid production and delivery
TWI698526B (en) * 2014-05-30 2020-07-11 美商綠陽生物科技及製藥公司 Feeder-free derivation of human-induced pluripotent stem cells with synthetic messenger rna
US11241505B2 (en) 2015-02-13 2022-02-08 Factor Bioscience Inc. Nucleic acid products and methods of administration thereof
CN105567642B (en) * 2016-02-01 2019-07-12 中国科学院生物物理研究所 A kind of preparation method of xeroderma pitmentosum human pluripotent stem cells
JP2019528284A (en) 2016-08-17 2019-10-10 ファクター バイオサイエンス インコーポレイテッド Nucleic acid product and method of administration thereof
CN107142244B (en) * 2017-07-03 2019-12-20 广州润虹医药科技股份有限公司 Culture medium, application thereof and method for inducing transformation of pluripotent stem cells into mesenchymal stem cells
BR112020018602A2 (en) * 2018-03-13 2020-12-29 The Board Of Trustees Of The Leland Stanford Junior University TRANSIENT CELL REPROGRAMMING FOR REVERSING CELLULAR AGING
EP3806873A1 (en) * 2018-06-16 2021-04-21 Luigi Warren Reprogramming cells with synthetic messenger rna
CA3137687A1 (en) * 2019-05-14 2020-11-19 Aleph Farms Ltd. Pluripotent cell aggregates and use thereof
US10501404B1 (en) 2019-07-30 2019-12-10 Factor Bioscience Inc. Cationic lipids and transfection methods

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011142832A2 (en) * 2010-05-13 2011-11-17 Whitehead Institute For Biomedical Research Stem cells derived under low oxygen conditions
WO2012012708A1 (en) * 2010-07-22 2012-01-26 Regents Of The University Of Minnesota Induced pluripotent stem cells
US20130059377A1 (en) * 2010-05-05 2013-03-07 Alysson Muotri Stem cell defined media for xeno-free and feeder free conditions and uses thereof
US20130065814A1 (en) * 2010-03-09 2013-03-14 Shanghai Institutes For Biological Sciences, Cas Inductive production of pluripotent stem cells using synthetic transcription factors

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5260432A (en) 1989-06-22 1993-11-09 Sloan-Kettering Institute For Cancer Research Human gamma retinoic acid receptor DNA
JP2008307007A (en) * 2007-06-15 2008-12-25 Bayer Schering Pharma Ag Human pluripotent stem cell induced from human tissue-originated undifferentiated stem cell after birth
SG160248A1 (en) * 2008-09-18 2010-04-29 Agency Science Tech & Res Use of novel monoclonal antibodies targeting human embryonic stem cells to characterize and kill induced pluripotent stem cells
EP2192174B1 (en) 2008-11-21 2015-11-11 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Reprogramming cells toward a pluripotent state
WO2010108126A2 (en) 2009-03-19 2010-09-23 Fate Therapeutics, Inc. Reprogramming compositions and methods of using the same
CN102625837B (en) * 2009-08-07 2015-01-14 国立大学法人京都大学 Method of efficiently establishing induced pluripotent stem cells
EP2699269A1 (en) * 2011-04-22 2014-02-26 Prosensa Technologies B.V. New compounds for treating, delaying and/or preventing a human genetic disorder such as myotonic dystrophy type 1 (dm1)
US8497124B2 (en) 2011-12-05 2013-07-30 Factor Bioscience Inc. Methods and products for reprogramming cells to a less differentiated state
WO2013126813A1 (en) 2012-02-22 2013-08-29 Amgen Inc. Autologous mammalian models derived from induced pluripotent stem cells and related methods
ES2729563T3 (en) 2012-05-13 2019-11-04 Allele Biotechnology & Pharmaceuticals Inc Feeder-free derivation of human induced pluripotent stem cells with synthetic messenger RNA
US10155929B2 (en) 2012-05-13 2018-12-18 Allele Biotechnology & Pharmaceuticals, Inc. Feeder-free derivation of human-induced pluripotent stem cells with synthetic messenger RNA

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130065814A1 (en) * 2010-03-09 2013-03-14 Shanghai Institutes For Biological Sciences, Cas Inductive production of pluripotent stem cells using synthetic transcription factors
US20130059377A1 (en) * 2010-05-05 2013-03-07 Alysson Muotri Stem cell defined media for xeno-free and feeder free conditions and uses thereof
WO2011142832A2 (en) * 2010-05-13 2011-11-17 Whitehead Institute For Biomedical Research Stem cells derived under low oxygen conditions
WO2012012708A1 (en) * 2010-07-22 2012-01-26 Regents Of The University Of Minnesota Induced pluripotent stem cells

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
WANG ET AL.: "Rapid and efficient reprogramming of somatic cells to induced pluripotent stem cells by retinoic acid receptor gamma and liver receptor homolog 1", PNAS, vol. 108, no. 45, 8 November 2011 (2011-11-08), pages 18283 - 18288, XP055102609 *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9422577B2 (en) 2011-12-05 2016-08-23 Factor Bioscience Inc. Methods and products for transfecting cells
US9376669B2 (en) 2012-11-01 2016-06-28 Factor Bioscience Inc. Methods and products for expressing proteins in cells
US9447395B2 (en) 2012-11-01 2016-09-20 Factor Bioscience Inc. Methods and products for expressing proteins in cells
US9464285B2 (en) 2012-11-01 2016-10-11 Factor Bioscience Inc. Methods and products for expressing proteins in cells
US9487768B2 (en) 2012-11-01 2016-11-08 Factor Bioscience Inc. Methods and products for expressing proteins in cells
US12006508B2 (en) 2020-06-25 2024-06-11 Factor Bioscience Inc. Methods and products for expressing proteins in cells

Also Published As

Publication number Publication date
US10155929B2 (en) 2018-12-18
EP2997130A2 (en) 2016-03-23
SG11201509368PA (en) 2015-12-30
EP2997130A4 (en) 2017-03-01
JP2021166553A (en) 2021-10-21
JP6971574B2 (en) 2021-11-24
JP2016521541A (en) 2016-07-25
MX2015015840A (en) 2016-08-11
WO2014190361A2 (en) 2014-11-27
SG10202006695TA (en) 2020-08-28
HK1222675A1 (en) 2017-07-07
CN105555949A (en) 2016-05-04
HK1224335A1 (en) 2017-08-18
EP3904504A1 (en) 2021-11-03
MX2021005715A (en) 2021-07-21
US20130302295A1 (en) 2013-11-14

Similar Documents

Publication Publication Date Title
WO2014190361A3 (en) Feeder-free derivation of human-induced pluripotent stem cells with synthetic messenger rna
WO2013173248A3 (en) Feeder-free derivation of human-induced pluripotent stem cells with synthetic messenger rna
WO2012135621A3 (en) Priming of pluripotent stem cells for neural differentiation
MY181513A (en) Cell culture compositions and methods for polypeptide production
PH12016500782A1 (en) Suspension and clustering of human pluripotent stem cells for differentation into pancreatic endocrine cells
IN2014MN01680A (en)
BRPI0819609A2 (en) DIFFERENTIATION OF HUMAN EMBRYONIC STEM CELLS
MX2013002406A (en) Differentiation of human embryonic stem cells.
MX2016001986A (en) Method for preparing rebaudioside m by using enzyme method.
SG10201906304TA (en) Use of perfusion decellularized liver for islet cell recellularization
MX2013003681A (en) Engineered nucleic acids and methods of use thereof.
MX2010000746A (en) Differentiation of human embryonic stem cells.
MX2010001335A (en) Differentiation of human embryonic stem cells.
WO2016061071A8 (en) Generation of keratinocytes from pluripotent stem cells and maintenance of keratinocyte cultures
EA201491526A8 (en) METHOD FOR CULTIVATING BOVINE AND PORK SPERMATOGONIAL STEM CELLS WITHOUT USING CELL-FEEDERS
MX2018014043A (en) Cell culture compositions with antioxidants and methods for polypeptide production.
MY191776A (en) Method for preparing electrocompetent yeast cells, and method for using said cells
WO2014087244A3 (en) Methods of producing rpe cells
MX2015011781A (en) Cell culture media and methods of antibody production.
WO2014027176A3 (en) Stem cell culture method
EA202190736A1 (en) METHODS AND COMPOSITIONS FOR INCREASING PROTEIN EXPRESSION AND / OR TREATMENT OF DISORDER ASSOCIATED WITH HAPLON INSUFFICIENCY
WO2015073625A3 (en) Synergistic genome-nonintegrating reprogramming by micrornas and transcription factors
PE20161326A1 (en) POWDER FORMULATION OF COMPOUND MEDIA AND PREPARATION METHOD OF LIQUID MEDIUM FOR CELL CULTURE
SG11201900989QA (en) Method for inducing differentiation of pluripotent stem cells in vitro
PH12016502343A1 (en) Feeder-free derivation of human-induced pluripotent stem cells with synthetic messenger rna

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 201480033794.X

Country of ref document: CN

ENP Entry into the national phase

Ref document number: 2016514171

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: MX/A/2015/015840

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2014801588

Country of ref document: EP

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14801588

Country of ref document: EP

Kind code of ref document: A2